Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1–Adiponectin Axis

Empagliflozin (EMPA) is a novel sodium-glucose cotransporter 2 inhibitor (SGLT2i) that produces protective cardiovascular-renal outcomes in patients with diabetes. However, the effects of EMPA on obesity-related kidney disease have not been determined. The heme oxygenase-1 (HO-1)–adiponectin axis is...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Tongtong, Zhang, Jingwen, Wu, Di, Shi, Junfeng, Kuang, Zengguang, Ma, Yuting, Xu, Qian, Chen, Bing, Kan, Chengxia, Sun, Xiaodong, Han, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248377/
https://www.ncbi.nlm.nih.gov/pubmed/35784553
http://dx.doi.org/10.3389/fendo.2022.907984

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248377/
https://www.ncbi.nlm.nih.gov/pubmed/35784553
http://dx.doi.org/10.3389/fendo.2022.907984

Ejemplares similares